PBMI Hosts Live Webinar with CEO of Frelii, Inc. on the Future of AI, Big DNA Data and Precision Dosing

Frelii, Inc. FRLI ("Frelii" or "the Company") today announced that Ian Jenkins, CEO of Frelii, will present a live webinar on "Using AI and Big DNA Data to Advance Drug Development and Delivery." The free webinar, hosted by the Pharmacy Benefit Management Institute (PBMI), will take place on Thursday, June 27, 2019 at 1:30 p.m. Eastern Time. Register for this highly anticipated event here.

"As artificial intelligence (AI) evolves, those in the pharmaceutical segment must become aware of the upcoming trends and the possibilities it unlocks for drug development, delivery and precision medicine," Jenkins said. "While AI and big data are delivering answers to previously unsolved questions, they are also uncovering new discoveries, creating new strategies for treatment and opening new fields of study that, even in the early stages, are beginning to deliver benefits that will positively impact human health and wellness for generations."

During this presentation, Ian Jenkins, CEO of Frelii, will discuss:

• Why cutting-edge technology is closing the gap in precision dosing
• How big data can reduce the cost of drug development and clinical trials
• How AI and whole genome analysis can predict physical and psychological effects of drug interaction in an individual body
• How physicians and pharmacists can leverage AI to move beyond murky recommendations of Medical Cannabis (where it is legal) into accurate, precise prescriptions for strain, form and dosage

Frelii Chief Executive Officer Ian Jenkins has a deep and abiding passion for artificial intelligence and how it relates to the human genome, particularly epigenetics and expression. Enabling the progress and advancement of these areas has been the focus of his professional life. Jenkins spent the early years of his career working hands-on in research labs at both medical universities and private institutions. Over the past decade, he has served as a senior executive and CEO in the biotech industry, leveraging his extensive background in physiology, technology startups, finance and product research and development.

The webinar will be hosted by PBMI, which is the nation's leading provider of research and education that informs, advises, and influences the industry on drug cost management. It offers research, continuing education, and web resources to help all critical stakeholders work better together to optimize the overall value of drug benefit programs.

Register for this free webinar presentation at this link: https://attendee.gotowebinar.com/register/7138041981091234573?source=frelii

About Frelii Inc.

Frelii Inc. is a biotech company that uses human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome. The results are aligned and leveraged against its AI, as a means of creating a very strong and powerful data platform for use by the Health & Wellness, Healthcare, Medical Cannabis and Pharmaceutical industries. Frelii's technology generates accurate and profoundly valuable insight into an individual's DNA. The company provides DNA Kit Packages and customized reporting for consumers, patients and healthcare providers to ensure the ideal treatment, drugs and dosing are a prime "fit" to the individual. For more information, please visit www.frelii.com. Frelii FRLI currently trades on the OTC Pink Open Market, which is operated by the OTC Markets Group. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.

Follow Frelii online at:

Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/

Safe Harbor Statement:

This release contains certain "forward-looking statements" relating to the business of the Company. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190619005211/en/